• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

DOVITINIB Drug Record

  • Summary
  • Interactions
  • Claims
  • DOVITINIB chembl:CHEMBL522892 Antineoplastic

    Alternate Names:

    CHIR-258
    GFKI-258
    NVP-TKI258
    TKI-258
    DOVITINIB
    CHIR 258
    4-AMINO-5-FLUORO-3-[5-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]QUINOLIN-2(1H)-ONE
    TKI258
    TKI 258
    chemidplus:405169-16-6
    chembl:CHEMBL522892
    drugbank:05928

    Drug Info:

    Drug Class Kinase Inhibitors
    FDA Approval not approved
    Drug Class Small molecule
    Drug Indications antineoplastic agent
    Pharmaceutical Developer Novartis
    Source Reported Drug Name(s) Dovitinib/TKI258
    Drug Class FGFR Inhibitor
    Drug Type small molecule
    Drug Groups investigational
    Drug Categories bcrp/abcg2 inducers
    Drug Categories bcrp/abcg2 inhibitors
    Drug Categories cytochrome p-450 cyp1a2 inducers
    Drug Categories cytochrome p-450 cyp1a2 inducers (strength unknown)
    Drug Categories cytochrome p-450 cyp2c19 inhibitors
    Drug Categories cytochrome p-450 cyp2c19 inhibitors (weak)
    Drug Categories cytochrome p-450 cyp3a inhibitors
    Drug Categories cytochrome p-450 cyp3a4 inhibitors
    Drug Categories cytochrome p-450 cyp3a4 inhibitors (weak)
    Drug Categories cytochrome p-450 enzyme inducers
    Drug Categories cytochrome p-450 enzyme inhibitors
    Drug Categories heterocyclic compounds, fused-ring
    Drug Categories oatp1b1/slco1b1 inhibitors
    Drug Categories oatp1b3 inhibitors
    Drug Categories p-glycoprotein inhibitors
    Drug Categories quinolines
    Drug Categories tyrosine kinase inhibitors
    Drug Categories ugt1a3 inhibitors
    Drug Categories ugt2b7 inhibitors
    (11 More Sources)

    Publications:

    Gozgit et al., 2012, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models., Mol. Cancer Ther.
    Williams et al., 2013, Oncogenic FGFR3 gene fusions in bladder cancer., Hum. Mol. Genet.
    Hänze et al., 2013, Epithelial mesenchymal transition status is associated with anti-cancer responses towards receptor tyrosine-kinase inhibition by dovitinib in human bladder cancer cells., BMC Cancer
    Hahn et al., 2017, A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157., Clin. Cancer Res.
    Goyal et al., 2017, Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma., Cancer Discov
    Lamont et al., 2011, Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo., Br. J. Cancer
    Nakanishi et al., 2015, Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1., Mol. Cancer Ther.
    Chang et al., 2016, Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity., Nat. Biotechnol.
    André et al., 2013, Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer., Clin. Cancer Res.
    Konecny et al., 2013, Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells., Mol. Cancer Ther.
    Dutt et al., 2008, Drug-sensitive FGFR2 mutations in endometrial carcinoma., Proc. Natl. Acad. Sci. U.S.A.
    Byron et al., 2013, The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors., Neoplasia
    Guagnano et al., 2012, FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor., Cancer Discov
    Künstlinger et al., 2015, FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro., Oncotarget
    Eritja N et al., 2014, Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells., Mol Cancer Ther
    Lim et al., 2016, Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study., Cancer
    Chase et al., 2007, Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome., Blood
    Li SQ et al., 2013, Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534)., PLoS One
    Yan D et al., 2017, Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas., Oncogene
    Quintela-Fandino et al., 2014, Selective activity over a constitutively active RET-variant of the oral multikinase inhibitor dovitinib: results of the CNIO-BR002 phase I-trial., Mol Oncol
    Weiss J et al., 2014, Interaction potential of the multitargeted receptor tyrosine kinase inhibitor dovitinib with drug transporters and drug metabolising enzymes assessed in vitro., Pharmaceutics
  • DOVITINIB   FGF3

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Drug family FGFR inhibitor
    Alteration FGF3:amp

    PMIDs:
    None found


    Sources:
    CGI

  • DOVITINIB   FGFR2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name dovitinib, TKI-258, CHIR-258
    Variant Effect gain-of-function

    PMIDs:
    22238366 26619011 23658459 23443805 18552176 23908597 23002168 26036639 24448819


    Sources:
    ClearityFoundationClinicalTrial DoCM JAX-CKB TdgClinicalTrial CIViC TALC MyCancerGenome CGI

  • DOVITINIB   FGFR3

    Interaction Score: 0.18

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Indication/Tumor Type bladder urothelial carcinoma
    Approval Status Preclinical - Cell culture

    PMIDs:
    22238366 23175443 24325461 27932416 28034880 21119661 25589496


    Sources:
    ClearityFoundationClinicalTrial CancerCommons DTC JAX-CKB TdgClinicalTrial CIViC TTD TALC MyCancerGenome GuideToPharmacology ChemblInteractions

  • DOVITINIB   FGF4

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Drug family FGFR inhibitor
    Alteration FGF4:amp

    PMIDs:
    None found


    Sources:
    CGI

  • DOVITINIB   CAMKK2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   CFLAR

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationClinicalTrial

  • DOVITINIB   MARK4

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   MAP3K10

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   RPS6KA5

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   PIM2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   FGFR1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    22238366 23658459 27315356 17698633


    Sources:
    ClearityFoundationClinicalTrial DTC JAX-CKB TdgClinicalTrial TALC MyCancerGenome GuideToPharmacology

  • DOVITINIB   TSSK1B

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   FGFR4

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24124571


    Sources:
    ClearityFoundationClinicalTrial CIViC

  • DOVITINIB   SIK2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   PHKG2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   NEK4

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   SRPK1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   CSF1R

    Interaction Score: 0.05

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False
    Direct Interaction? False

    PMIDs:
    28759044


    Sources:
    ClearityFoundationClinicalTrial DTC CIViC GuideToPharmacology

  • DOVITINIB   IKBKE

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   SGK2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   PRKX

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   FLT1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor
    Direct Interaction yes
    Reported Cancer Type Prostate

    PMIDs:
    None found


    Sources:
    ClearityFoundationClinicalTrial CancerCommons DTC TdgClinicalTrial GuideToPharmacology ChemblInteractions

  • DOVITINIB   PDGFRB

    Interaction Score: 0.04

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name dovitinib, TKI-258, CHIR-258
    Novel drug target Established target
    Specific Action of the Ligand Inhibition

    PMIDs:
    None found


    Sources:
    ClearityFoundationClinicalTrial DTC TdgClinicalTrial GuideToPharmacology ChemblInteractions

  • DOVITINIB   NEK2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   CAMK2D

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   MAP3K20

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   PDGFRA

    Interaction Score: 0.04

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Platelet-derived growth factor receptor inhibitor
    Direct Interaction yes
    Specific Action of the Ligand Inhibition

    PMIDs:
    None found


    Sources:
    ClearityFoundationClinicalTrial DTC GuideToPharmacology ChemblInteractions

  • DOVITINIB   RET

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type sensitive
    Approval Status Phase I

    PMIDs:
    25103625


    Sources:
    ClearityFoundationClinicalTrial DTC JAX-CKB

  • DOVITINIB   MELK

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   MARK2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   FLT4

    Interaction Score: 0.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor
    Direct Interaction yes
    Trial Name dovitinib, TKI-258, CHIR-258

    PMIDs:
    None found


    Sources:
    ClearityFoundationClinicalTrial DTC TdgClinicalTrial GuideToPharmacology ChemblInteractions

  • DOVITINIB   KIT

    Interaction Score: 0.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Stem cell growth factor receptor inhibitor
    Direct Interaction yes
    Specific Action of the Ligand Inhibition

    PMIDs:
    None found


    Sources:
    ClearityFoundationClinicalTrial DTC GuideToPharmacology ChemblInteractions

  • DOVITINIB   PAK4

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   TYRO3

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   IRAK1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   BRSK1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   CAMK2G

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   PKN2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   MARK3

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   ACVR1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   ITK

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   CSNK1D

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   HCK

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   CLK2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   LIMK1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   LRRK2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   KDR

    Interaction Score: 0.02

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False
    Direct Interaction? False

    PMIDs:
    None found


    Sources:
    ClearityFoundationClinicalTrial DTC TdgClinicalTrial TALC GuideToPharmacology ChemblInteractions

  • DOVITINIB   CDK7

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   MAP4K2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   MST1R

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   STK3

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   AXL

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   PRKAA1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   CHEK2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   PLK4

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   MINK1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   NTRK1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationClinicalTrial DTC

  • DOVITINIB   RPS6KB1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   FLT3

    Interaction Score: 0.02

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Tyrosine-protein kinase receptor FLT3 inhibitor
    Direct Interaction yes
    Specific Action of the Ligand Inhibition

    PMIDs:
    None found


    Sources:
    DTC GuideToPharmacology ChemblInteractions

  • DOVITINIB   TYK2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   PRKD2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   INSR

    Interaction Score: 0.02

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False
    Direct Interaction? False

    PMIDs:
    None found


    Sources:
    DTC GuideToPharmacology

  • DOVITINIB   SLK

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   PDPK1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   MAP4K5

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   RPS6KA3

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   PRKCD

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   NTRK3

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   ROCK2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   PRKD3

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   BTK

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   MAP4K4

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   BLK

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   FYN

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   MAP2K2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   LYN

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   MAPK10

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   MAPK8

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   NTRK2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   CLK4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   MAP2K1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   CHEK1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   ALK

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   AURKB

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   LCK

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   NR1I2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    suppressor (inhibitory)

    Interaction Info:

    PMIDs:
    25521244


    Sources:
    DrugBank

  • DOVITINIB   ABL1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   JAK2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   SRC

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   EGFR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False
    Direct Interaction? False

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • DOVITINIB   YES1

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DrugBank: DB05928

    • Version: 5.1.7

    Alternate Names:
    DOVITINIB DrugBank Drug Name
    405169-16-6 CAS Number
    CHEMBL522892 ChEMBL ID

    Drug Info:
    Drug Type small molecule
    Drug Groups investigational
    Drug Categories bcrp/abcg2 inducers

    Publications:
    Weiss J et al., 2014, Interaction potential of the multitargeted receptor tyrosine kinase inhibitor dovitinib with drug transporters and drug metabolising enzymes assessed in vitro., Pharmaceutics

  • MyCancerGenome: DOVITINIB

    • Version: 20-Jun-2017

    Alternate Names:
    TKI258 Development Name
    CHIR-258 Development Name
    DOVITINIB Generic Name

    Drug Info:
    Drug Class Kinase Inhibitors

    Publications:

  • CancerCommons: DOVITINIB

    • Version: 25-July-2013

    Alternate Names:
    4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one PubChem Drug Name
    9886808 PubChem Drug ID
    Dovitinib Drug Trade Name

    Drug Info:
    Drug Class FGFR Inhibitor
    Source Reported Drug Name(s) Dovitinib/TKI258
    Pharmaceutical Developer Novartis

    Publications:

  • TdgClinicalTrial: DOVITINIB

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small molecule
    FDA Approval not approved

    Publications:

  • JAX-CKB: Dovitinib

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Gozgit et al., 2012, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models., Mol. Cancer Ther.
    André et al., 2013, Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer., Clin. Cancer Res.
    Lim et al., 2016, Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study., Cancer

  • DoCM: DOVITINIB

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Gozgit et al., 2012, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models., Mol. Cancer Ther.
    Chang et al., 2016, Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity., Nat. Biotechnol.
    Dutt et al., 2008, Drug-sensitive FGFR2 mutations in endometrial carcinoma., Proc. Natl. Acad. Sci. U.S.A.

  • CIViC: DOVITINIB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Hahn et al., 2017, A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157., Clin. Cancer Res.
    Lamont et al., 2011, Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo., Br. J. Cancer
    Eritja N et al., 2014, Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells., Mol Cancer Ther

  • DTC: DOVITINIB

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL522892 ChEMBL Drug ID

    Drug Info:

    Publications:

  • GuideToPharmacology: 178102585

    • Version: 29-September-2020

    Alternate Names:
    DOVITINIB GuideToPharmacology Ligand Name

    Drug Info:

    Publications:

  • TALC: DOVITINIB

    • Version: 12-May-2016

    Alternate Names:
    DOVITINIB Primary Drug Name
    DOVITINIB Drug Generic Name
    TKI-258 Drug Synonym

    Drug Info:

    Publications:

  • TTD: TKI258

    • Version: 2020.06.01

    Alternate Names:
    D07OZR TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL522892

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: DOVITINIB

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

  • CGI: Dovitinib

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL522892

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21